Devices and equipment for evaluating cognitive impairment in people with intracranial atherosclerotic stenosis

Abstract

The present disclosure provides a cognitive impairment assessment device and equipment for people with intracranial atherosclerotic stenosis, the device comprising: a neuroimaging data acquisition module, a cognitive impairment assessment module and a result output module; the neuroimaging data acquisition module is used to obtain the neuroimaging assessment results of the person to be tested; the cognitive impairment assessment module is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to determine the cognitive function status of the person to be tested; the result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results and the cognitive function status. The cognitive impairment assessment device provided by the present disclosure can efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis.

Description

Technical Field

[0001] The present disclosure relates to the field of data processing technology, and in particular to a device and equipment for evaluating cognitive impairment in people with intracranial atherosclerotic stenosis. Background Art

[0002] The existing cognitive impairment assessment device usually sets any one of the 90-minute full-set assessment, 30-minute assessment and 5-minute assessment, which are cognitive assessment methods for vascular cognitive impairment recommended by international consensus. However, the full-set assessment is the most reliable, but it takes a long time, has higher operational complexity and professionalism, and is not suitable for primary hospitals and hospitals with greater pressure on cognitive impairment clinics; the 30-minute assessment has low sensitivity, and the selected test is determined by expert voting, and no reliable cognitive data support and imaging data verification are obtained; the 5-minute assessment is a complete set rather than a cognitive domain test set, which is only suitable for screening cognitive impairment and cannot be used for specific cognitive function status determination; and the above three tests are only verified and used in patients after stroke. Therefore, the existing cognitive impairment assessment device cannot efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis. Therefore, how to efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis is a technical problem that needs to be solved urgently by those skilled in the art. Summary of the invention

[0003] In view of this, the present disclosure proposes a cognitive impairment assessment device and equipment for people with intracranial atherosclerotic stenosis, which can efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis.

[0004] According to a first aspect of the present disclosure, a device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis is provided, comprising:

[0005] Neuroimaging data acquisition module, cognitive impairment assessment module and result output module;

[0006] The neuroimaging data acquisition module is used to obtain the neuroimaging assessment results of the person to be tested;

[0007] The cognitive impairment assessment module is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to determine the cognitive function status of the person to be tested;

[0008] The result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results and the cognitive function status.

[0009] In a possible implementation, the neuroimaging assessment results include head MRI assessment results and head MRA assessment results.

[0010] In a possible implementation, the cognitive impairment assessment module includes: an assessment unit, a test score conversion unit, and a cognitive function state output unit;

[0011] The evaluation unit is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to obtain a test score of each cognitive domain of the person to be tested;

[0012] The test score conversion unit is used to calculate the Z score corresponding to the test score of each cognitive domain based on the test score of each cognitive domain, wherein the Z score is used to represent the relative level of the test score of each cognitive domain of the person to be tested in the population;

[0013] The cognitive function status output unit is used to output the cognitive function status of the person to be tested based on the Z score corresponding to the test score of each cognitive domain.

[0014] In a possible implementation, the simplified ICAS-related cognitive impairment test includes a life ability domain test, and the test scores of each cognitive domain of the person to be tested include a test score of the life ability domain;

[0015] The cognitive function status output unit, when outputting the cognitive function status of the person to be tested based on the Z score corresponding to the test score of each cognitive domain, is specifically used to:

[0016] obtaining a test score of the life ability domain;

[0017] Based on the Z scores corresponding to the test scores of the cognitive domains and the test scores of the life ability domains, the cognitive function status of the person to be tested is output.

[0018] In a possible implementation, the cognitive function state includes: different cognitive levels, wherein the different cognitive levels correspond to different degrees of cognitive states.

[0019] In a possible implementation, the device further includes: a vascular risk factor assessment module;

[0020] The vascular risk factor assessment module is used to obtain the vascular risk factors of the person to be tested;

[0021] The result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results, the cognitive function status and the vascular risk factors.

[0022] In a possible implementation, the vascular risk factor includes at least one of hypertension, diabetes, hyperlipidemia, smoking and drinking.

[0023] In a possible implementation, the device further includes: a simplified ICAS-related cognitive impairment test building module;

[0024] The simplified ICAS-related cognitive impairment test construction module is used to construct a simplified ICAS-related cognitive impairment test.

[0025] In a possible implementation, the simplified ICAS-related cognitive impairment test construction module includes: a sample data acquisition module, a first test screening module, a second test screening module, and a simplified ICAS-related cognitive impairment test generation module;

[0026] The sample data acquisition module is used to obtain the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full assessment, and the Z scores corresponding to each test score, wherein the ICAS clinical subjects include healthy subjects, asymptomatic subjects, and symptomatic subjects, and the Z scores corresponding to the test scores reflect the relative levels of the test scores in the normal population;

[0027] The first test screening module is used to traverse various tests in the 90-minute full set of assessments, and for the traversed current test, perform a pairwise comparison of the test scores of the current test between healthy subjects, asymptomatic subjects and symptomatic subjects according to the basic information of each ICAS clinical subject and the test score of the current test, to obtain the significance score of each comparison group, and when the significance score of at least one comparison group among the comparison group consisting of the healthy subjects and the asymptomatic subjects and the comparison group consisting of the asymptomatic subjects and the symptomatic subjects is less than or equal to a preset significance level, the current test is screened out as the initial test, and the traversal is completed to obtain all the screened initial tests;

[0028] The second test screening module is used to traverse each cognitive domain, and for the traversed current cognitive domain, determine whether the initial test corresponding to the current cognitive domain is unique. If the initial test corresponding to the current cognitive domain is unique, directly screen the initial test corresponding to the current cognitive domain as the target test of the current cognitive domain; if the initial test corresponding to the current cognitive domain is not unique, traverse each initial test under the current cognitive domain, and for the traversed current initial test, perform linear regression analysis on the basic information of each ICAS clinical subject and the Z score corresponding to the test score of the current initial test to obtain the asymptomatic subjects in the current initial test. Values ​​and symptoms of the subjects Value, based on the asymptomatic subjects Values ​​and symptoms of the subjects value, calculate the current initial test The value is summed up, and after the traversal of each of the initial tests under the current cognitive domain is completed, the value of each of the initial tests under the current cognitive domain is obtained. The total value will The initial test with the largest total value is selected as the target test under the current cognitive domain; after the traversal of each cognitive domain is completed, the target test corresponding to each cognitive domain is obtained, wherein the asymptomatic subject The value represents the Z score reduction of the asymptomatic subject relative to the healthy subject, and the The value represents the Z score reduction of the symptomatic subjects relative to the healthy subjects;

[0029] The simplified ICAS-related cognitive impairment test generation module is used to sequentially combine the target tests corresponding to each cognitive domain to obtain the simplified ICAS-related cognitive impairment test.

[0030] According to a second aspect of the present disclosure, a device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis is provided, specifically comprising the device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis as described in any one of the first aspects of the present disclosure.

[0031] The present disclosure provides a cognitive impairment assessment device and equipment for people with intracranial atherosclerotic stenosis, the device comprising: a neuroimaging data acquisition module, a cognitive impairment assessment module and a result output module; the neuroimaging data acquisition module is used to obtain the neuroimaging assessment results of the person to be tested; the cognitive impairment assessment module is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to determine the cognitive function status of the person to be tested; the result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results and the cognitive function status. The cognitive impairment assessment device provided by the present disclosure can efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis.

[0032] Further features and aspects of the present disclosure will become apparent from the following detailed description of exemplary embodiments with reference to the attached drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments, features, and aspects of the disclosure and, together with the description, serve to explain the principles of the disclosure.

[0034] Figure 1A schematic block diagram of a device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis according to an embodiment of the present disclosure is shown.

[0035] Figure 2 A schematic diagram showing the test sequence of each test in a simplified ICAS-related cognitive impairment test according to an embodiment of the present disclosure is shown.

[0036] Figure 3 A flow chart of determining cognitive function status based on a simplified ICAS-related cognitive impairment test according to an embodiment of the present disclosure is shown. DETAILED DESCRIPTION

[0037] Various exemplary embodiments, features and aspects of the present disclosure will be described in detail below with reference to the accompanying drawings. The same reference numerals in the accompanying drawings represent elements with the same or similar functions. Although various aspects of the embodiments are shown in the accompanying drawings, the drawings are not necessarily drawn to scale unless otherwise specified.

[0038] The word “exemplary” is used exclusively herein to mean “serving as an example, example, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.

[0039] In addition, in order to better illustrate the present disclosure, numerous specific details are given in the following specific embodiments. It should be understood by those skilled in the art that the present disclosure can also be implemented without certain specific details. In some examples, methods, means, components and circuits well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present disclosure.

[0040] <Method Example>

[0041] Figure 1 FIG. 1 is a schematic block diagram of a device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis according to an embodiment of the present disclosure. Figure 1 As shown, the device 100 includes: a neuroimaging data acquisition module 110 , a cognitive impairment assessment module 120 and a result output module 130 .

[0042] Specifically, the neuroimaging data acquisition module 110 is used to acquire the neuroimaging evaluation results of the person to be tested. Here, the person to be tested is a person who needs to be tested for cognitive impairment related to intracranial atherosclerotic stenosis.

[0043] It should be noted here that before obtaining the neuroimaging assessment results of the person to be tested, it is necessary to first shoot the neuroimaging of the person to be tested to obtain the neuroimaging image of the person to be tested. Then the doctor evaluates the neuroimaging image of the person to be tested to obtain the neuroimaging assessment results of the person to be tested. After obtaining the neuroimaging assessment results of the person to be tested, the doctor can trigger the neuroimaging data acquisition control in the assessment interface pushed and displayed by the cognitive impairment assessment device. When the neuroimaging data acquisition control is triggered, the neuroimaging data acquisition interface will be pushed and displayed, and the doctor can input the neuroimaging assessment results of the person to be tested through the neuroimaging data acquisition interface, and trigger the confirmation control in the neuroimaging data acquisition interface after the neuroimaging assessment results are output. When the confirmation control in the neuroimaging data acquisition interface is triggered, the neuroimaging data acquisition module 110 can obtain the neuroimaging assessment results of the person to be tested.

[0044] In a possible implementation, the neuroimaging assessment results may include head MRI assessment results and head MRA assessment results. Among them, the head MRI assessment results include at least one of whether the key brain area is infarcted, the Fasekas score of white matter lesions, the number of cavities in the brain, and the grading score of cerebral lobe atrophy. The head MRA assessment results include at least one of whether the intracranial artery is stenotic and the proportion of intracranial artery stenosis.

[0045] In some possible implementations, the head MRI evaluation results may be replaced by CT evaluation results, and the head MRA evaluation results may be replaced by CTA evaluation results.

[0046] The cognitive impairment assessment module 120 is used to perform a pre-constructed simplified ICAS-related cognitive impairment test (i.e., a simplified intracranial artery atherosclerositicstenosis (ICAS)-related cognitive impairment test) on the testee to determine the cognitive function state of the testee. The cognitive function state of the testee includes: different cognitive levels, wherein different cognitive levels correspond to different degrees of cognitive state. In a possible implementation, the cognitive level can be divided into three different cognitive levels: no cognitive impairment, mild cognitive impairment, and dementia.

[0047] It should be noted here that a simplified ICAS-related cognitive impairment test construction module can be configured in the cognitive impairment assessment device to construct a simplified ICAS-related cognitive impairment test, and the constructed simplified ICAS-related cognitive impairment test is associated with the cognitive impairment assessment module 120. In this way, the simplified ICAS-related cognitive impairment test can be performed on the testee through the cognitive impairment assessment module 120 to determine the cognitive function status of the testee.

[0048] In a possible implementation, the simplified ICAS-related cognitive impairment test construction module may include: a sample data acquisition module, a first test screening module, a second test screening module, and a simplified ICAS-related cognitive impairment test generation module.

[0049] Among them, the sample data acquisition module is used to obtain the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full assessment, and the Z scores corresponding to each test score. Among them, ICAS clinical subjects include healthy subjects, asymptomatic subjects, and symptomatic subjects. The Z scores corresponding to the test scores reflect the relative level of the test scores in the normal population and can be used to compare different tests. Among them, healthy subjects are subjects with non-intracranial artery stenosis but cognitive decline, asymptomatic subjects are subjects with intracranial artery stenosis but no cognitive impairment, and symptomatic subjects are subjects with intracranial artery stenosis and cognitive impairment.

[0050] Specifically, for each ICAS clinical subject, first record the basic information such as name, gender, age, education level and classification, where the classification characterizes whether the ICAS clinical subject is a healthy subject, an asymptomatic subject, or a symptomatic subject. Then, perform a 90-minute full set of assessments on the subject to obtain the test scores of each test, and calculate the Z score corresponding to the test score of each test. Finally, store the basic information, the test scores of each test obtained by the 90-minute full set of assessments, and the Z score corresponding to the test score of each test as a sample data. After completing the sample data collection of all ICAS clinical subjects, sample data including the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full set of assessments, and the Z score corresponding to each test score can be obtained.

[0051] After obtaining the sample data, the simplified ICAS-related cognitive impairment test construction control can be triggered in the evaluation interface pushed and displayed by the cognitive impairment evaluation device. When the simplified ICAS-related cognitive impairment test construction control is triggered, the simplified ICAS-related cognitive impairment test construction interface will be pushed and displayed, which includes the sample data acquisition control. When the sample data acquisition control is triggered, the sample data acquisition interface will be pushed and displayed, and the doctor can import the sample data through the sample data acquisition interface, and trigger the confirmation control on the sample data acquisition interface after the sample data import is completed. When the confirmation control in the sample data acquisition interface is triggered, the sample data acquisition module can obtain the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full evaluation, and the Z scores corresponding to each test score.

[0052] It should be noted that the 90-minute full assessment includes the following: 1. Overall cognitive test: mini-mental state examination (MMSE); 2. Life skills test: activities of daily living scale (ADL); 3. Cognitive ability test: (1) Memory domain test: auditory verbal learning test (AVLT, Chinese protocol), paired associate word learning test (ALT), Rey complex figure recall test (Rey recall); (2) Visual-spatial domain test: Rey complex figure copy test (Rey copy); (3) Attention test: trailmaking test A (TMT-A), digit span test (DST); (4) Executive domain test: trailmaking test A and B (TMT-A&B), symbol digit modalities test (SDMT) 】, clock drawing test (CDT) ; (5) Language domain test: Boston naming test (BNT) , category verbal fluency test (VFT) ; (6) Calculation domain test: calculation of Wechsler Adult Intelligence Scale (Calculation) .

[0053] After obtaining the test scores for each test in the full 90-minute assessment, the Z score corresponding to each test score can be calculated based on the following calculation formula.

[0054] z score = (test score - average score of the normal population on the test) / standard deviation of the normal population on the test

[0055] The average score of the normal population and the standard deviation of the normal population in the formula can be obtained by performing the test on a set amount of normal population and calculating the mean and standard deviation of the test results of each normal population. The normal population here refers to the population that has been diagnosed and excluded from cognitive impairment.

[0056] After obtaining the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full assessment, and the Z scores corresponding to each test score, the first test screening module can be started.

[0057] The first test screening module is used to traverse the various tests in the 90-minute full set of assessments. For the current test traversed, the test scores of the current test between healthy subjects, asymptomatic subjects and symptomatic subjects are compared in pairs according to the basic information of each ICAS clinical subject and the test score of the current test, and the significance scores of each comparison group are obtained. Among the comparison groups composed of healthy subjects and asymptomatic subjects and the comparison groups composed of asymptomatic subjects and symptomatic subjects, at least one comparison group has a significance score less than or equal to a preset significance level, and the current test is screened out as the initial test. The traversal is completed to obtain all the initial tests screened out. Among them, the preset significance level can be 0.05.

[0058] In a possible implementation, when the test scores of the current test between healthy subjects, asymptomatic subjects and symptomatic subjects are compared in pairs according to the basic information of each ICAS clinical subject and the test scores of the current test, and the significance scores of each comparison group are obtained, it can be implemented based on the one-way variance analysis in SPSS software. How to obtain the significance scores of each comparison group based on the one-way variance analysis in SPSS software is common knowledge in the art and will not be repeated here.

[0059] In a possible implementation, when the test scores of the current test between healthy subjects, asymptomatic subjects and symptomatic subjects are compared pairwise based on the basic information of each ICAS clinical subject and the test score of the current test, the test score of the current test of each ICAS clinical subject is corrected using the Bonferroni algorithm in the one-way analysis of variance based on the age, gender and education level in the basic information of each ICAS clinical subject, and the significance score corresponding to each comparison group is analyzed based on the corrected test score.

[0060] After all initial tests are screened out through the first test screening module, the second test screening module can be started. The second test screening module is used to traverse each cognitive domain, and for the current cognitive domain that has been traversed, determine whether the initial test corresponding to the current cognitive domain is unique. If the initial test corresponding to the current cognitive domain is unique, directly screen out the initial test corresponding to the current cognitive domain as the target test of the current cognitive domain; if the initial test corresponding to the current cognitive domain is not unique, traverse each initial test under the current cognitive domain, and for the current initial test that has been traversed, perform a linear regression analysis on the basic information of each ICAS clinical subject and the Z score corresponding to the test score of the current initial test, and obtain the asymptomatic subjects in the current initial test. Values ​​and symptoms of the subjects Values, based on asymptomatic subjects Values ​​and symptoms of the subjects Value, calculate the current initial test After the initial tests in the current cognitive domain are traversed, the total value of each initial test in the current cognitive domain is obtained. The total value will The initial test with the largest total value is selected as the target test under the current cognitive domain; after the traversal of each cognitive domain is completed, the target test corresponding to each cognitive domain is obtained, among which the asymptomatic subjects The values ​​represent the reduction in Z scores of asymptomatic subjects relative to healthy controls, and the The values ​​represent the reduction in Z scores of symptomatic subjects relative to healthy controls.

[0061] In a possible implementation, a linear regression analysis is performed on the basic information of each ICAS clinical subject and the Z score corresponding to the test score of the current initial test to obtain the Z score of the asymptomatic subjects in the current initial test. Values ​​and symptoms of the subjects How to use the linear regression analysis in SPSS software to analyze the asymptomatic subjects in the current initial test? Values ​​and symptoms of the subjects The value is common knowledge in the art and will not be elaborated here.

[0062] In a possible implementation, when performing linear regression analysis on the basic information of each ICAS clinical subject and the Z score corresponding to the test score of the current initial test, it also includes correcting each test score based on the gender in the basic information of each ICAS clinical subject, and performing linear regression analysis based on each corrected test score.

[0063] After the target tests corresponding to each cognitive domain are screened out by the second test screening module, the simplified ICAS-related cognitive impairment test generation module can be started. The simplified ICAS-related cognitive impairment test generation module is used to sequentially combine the target tests corresponding to each cognitive domain to obtain a simplified ICAS-related cognitive impairment test. Specifically, the sequential combination of each target test is performed in the order of memory-execution-visuospatial-language-computational domain, wherein the N3, N4 and N5 tests in the AVLT need to be separated by a certain time, therefore, they are inserted into the sorted target tests according to the required interval time.

[0064] In a possible implementation, the simplified ICAS-related cognitive impairment test obtained through the above steps includes N1, N2, N3 tests in AVLT, TMT test, Rey copy test, N4 test in AVLT, BNT test, Cauculation test, ADL test and N5 test in AVLT. The test order of each test is as follows: Figure 2 As shown. Among them, the test score of the AVLT test is expressed as the number of words recalled 5 times (full score 60 points), the test score of the TMT test is expressed as the time used to complete the test in seconds, the test score of the Rey copy test is expressed as the accuracy of the graphics and positions of the 18 graphics required to be drawn (full score 36 points), the test score of the BNT test is expressed as the number of correctly named graphics among the 30 graphics displayed (full score 30 points), the test score of the Calculation test is expressed as the number of correct questions among the 14 calculation questions, and the test score of the ADL test is the total score of the 14 questions (the minimum score is 14 points, and the higher the score, the worse the ability to live independently).

[0065] By constructing this simplified ICAS-related cognitive impairment test, it only takes 45 minutes to accurately complete the accurate assessment of the cognitive function status of the testee, which significantly improves the efficiency of cognitive function status assessment. Compared with the 90-minute complete set of assessments, the sensitivity and specificity of this simplified ICAS-related cognitive impairment test can reach 91.5% and 90.7% respectively, which shows that this set of test applications can achieve the effect of the 90-minute complete set of tests. Among them, the sensitivity (Sensitivity), also known as the true positive rate, the larger this value, the more sensitive the diagnostic test is, that is, it can correctly diagnose more people who are actually sick as positive. Specificity (Specificity), also known as the true negative rate, the larger this value, the more accurate the diagnostic test is, that is, it can correctly diagnose more people who are not sick as negative. These two indicators are important tools for evaluating the performance of diagnostic tests. Among them, sensitivity reflects the ability of the diagnostic test to correctly identify patients in the sick population, while specificity reflects the ability of the diagnostic test to correctly exclude non-patients in the non-sick population.

[0066] After obtaining the simplified ICAS-related cognitive impairment test, the simplified ICAS-related cognitive impairment test can be associated with the cognitive impairment assessment module 120, so that the simplified ICAS-related cognitive impairment test can be performed on the testee through the cognitive impairment assessment module 120 to determine the cognitive function status of the testee.

[0067] In a possible implementation, the cognitive impairment assessment module includes: an assessment unit, a test score conversion unit, and a cognitive function state output unit.

[0068] Specifically, the assessment unit is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the testee to obtain the test scores of each cognitive domain of the testee.

[0069] The test score conversion unit is used to calculate the Z score corresponding to the test score of each cognitive domain based on the test score of each cognitive domain. The calculation process of the Z score is as mentioned above and will not be repeated here.

[0070] The cognitive function status output unit is used to output the cognitive function status of the person to be tested based on the Z score corresponding to the test score of each cognitive domain.

[0071] In an embodiment in which the simplified ICAS-related cognitive impairment test includes a life ability test, the test scores of each cognitive domain of the person to be tested include a life ability test score;

[0072] The cognitive function state output unit, when outputting the cognitive function state of the person to be tested based on the Z score corresponding to the test score of each cognitive domain, is specifically used to:

[0073] Obtaining scores on life skills tests;

[0074] Based on the Z score corresponding to the test score of each cognitive domain and the test score of life ability, the cognitive function status of the person to be tested is output. Specifically, if the Z score is ≤-1.5, it means that the test score is ≤1.5 times the norm standard deviation compared with the norm, wherein the norm standard deviation is the standard deviation of the test of the normal population used when calculating the Z score. When at least one test score is ≤-1.5 times the norm standard deviation compared with the norm and the test score of life ability is less than or equal to 16, the cognitive function status of the person to be tested is judged to be mild cognitive impairment; when at least one test score is ≤-1.5 times the norm standard deviation compared with the norm and the test score of life ability is greater than 16, the cognitive function status of the person to be tested is judged to be dementia. When the test scores of each cognitive domain are greater than -1.5 times the norm standard deviation, the cognitive function status of the person to be tested is judged to be cognitively intact.

[0075] After obtaining the neuroimaging assessment results and cognitive function status of the person to be tested, the result output module 130 can be started. The result output module 130 is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results and cognitive function status.

[0076] In an embodiment where the neuroimaging assessment results include head MRI assessment results and head MRA assessment results, if the head MRI assessment results of the person to be tested meet at least one of the following conditions: infarction in key brain areas, Fasekas score of white matter lesions greater than 2 points, number of cavities in the brain greater than 2 points, and grading score of lobar atrophy greater than 1 point, and according to the head MRA assessment results it is determined that there is stenosis of the intracranial artery and the proportion of intracranial artery stenosis is greater than 50%, and the cognitive function status of the person to be tested is dementia or mild cognitive impairment, then it is determined that the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis.

[0077] In a possible implementation, the device may also include: a vascular risk factor assessment module; the vascular risk factor assessment module is used to obtain the vascular risk factors of the person to be tested; wherein the vascular risk factors include at least one of hypertension, diabetes, hyperlipidemia, smoking and drinking.

[0078] In an embodiment in which the cognitive impairment assessment device 100 includes a neuroimaging data acquisition module 110, a cognitive impairment assessment module 120, a vascular risk factor assessment module, and a result output module 130, and the neuroimaging assessment results acquired by the neuroimaging data acquisition module 110 include a head MRI assessment result and a head MRA assessment result, and the vascular risk factors include at least one of hypertension, diabetes, hyperlipidemia, smoking, and drinking, the result output module 130, when determining whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results, the cognitive function status, and the vascular risk factors, as follows: Figure 3 As shown, that is, if the head MRI assessment results of the person to be tested meet at least one of the following conditions: infarction in key brain areas, Fasekas score of white matter lesions greater than 2 points, the number of cavities in the brain greater than 2, and the grading score of cerebral lobe atrophy greater than or equal to 1 point, and according to the head MRA assessment results, it is determined that there is stenosis of the intracranial artery and the proportion of intracranial artery stenosis is greater than 50%, and the vascular risk factors of the person to be tested include at least one of hypertension, diabetes, hyperlipidemia, smoking and drinking, and the cognitive function status of the person to be tested is dementia or mild cognitive impairment, then the person to be tested is determined to have cognitive impairment related to intracranial atherosclerotic stenosis.

[0079] The present disclosure provides a cognitive impairment assessment device for a group of people with intracranial atherosclerotic stenosis, including: a neuroimaging data acquisition module, a cognitive impairment assessment module and a result output module; the neuroimaging data acquisition module is used to obtain the neuroimaging assessment results of the person to be tested; the cognitive impairment assessment module is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to determine the cognitive function status of the person to be tested; the result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis according to the neuroimaging assessment results and the cognitive function status. The cognitive impairment assessment device provided by the present disclosure can efficiently and accurately determine the cognitive function status of people with intracranial atherosclerotic stenosis.

[0080] <Equipment Embodiment>

[0081] In the present embodiment, a device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis is provided. The device includes any device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis as described in the device embodiments.

[0082] The embodiments of the present disclosure have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements to the technology in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A device for evaluating cognitive impairment in people with intracranial atherosclerotic stenosis, characterized in that: include: Neuroimaging data acquisition module, cognitive impairment assessment module and result output module; The neuroimaging data acquisition module is used to obtain the neuroimaging assessment results of the person to be tested; The cognitive impairment assessment module is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to determine the cognitive function status of the person to be tested, wherein ICAS refers to intracranial atherosclerotic stenosis; The result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results and the cognitive function status; The device further comprises: a simplified ICAS-related cognitive impairment test construction module, wherein the simplified ICAS-related cognitive impairment test construction module is used to construct a simplified ICAS-related cognitive impairment test; The simplified ICAS-related cognitive impairment test construction module includes: a sample data acquisition module, a first test screening module, a second test screening module and a simplified ICAS-related cognitive impairment test generation module; The sample data acquisition module is used to obtain the basic information of a set number of ICAS clinical subjects, the test scores of each test in the 90-minute full assessment, and the Z scores corresponding to each test score, wherein the ICAS clinical subjects include healthy subjects, asymptomatic subjects, and symptomatic subjects, and the Z scores corresponding to the test scores reflect the relative levels of the test scores in the normal population; The first test screening module is used to traverse various tests in the 90-minute full set of assessments, and for the traversed current test, perform a pairwise comparison of the test scores of the current test between healthy subjects, asymptomatic subjects and symptomatic subjects according to the basic information of each ICAS clinical subject and the test score of the current test, to obtain the significance score of each comparison group, and when the significance score of at least one comparison group among the comparison group consisting of the healthy subjects and the asymptomatic subjects and the comparison group consisting of the asymptomatic subjects and the symptomatic subjects is less than or equal to a preset significance level, the current test is screened out as the initial test, and the traversal is completed to obtain all the screened initial tests; The second test screening module is used to traverse each cognitive domain, and for the traversed current cognitive domain, determine whether the initial test corresponding to the current cognitive domain is unique. If the initial test corresponding to the current cognitive domain is unique, directly screen the initial test corresponding to the current cognitive domain as the target test of the current cognitive domain; if the initial test corresponding to the current cognitive domain is not unique, traverse each initial test under the current cognitive domain, and for the traversed current initial test, perform linear regression analysis on the basic information of each ICAS clinical subject and the Z score corresponding to the test score of the current initial test to obtain the asymptomatic subjects in the current initial test. Values ​​and symptoms of the subjects Value, based on the asymptomatic subjects Values ​​and symptoms of the subjects value, calculate the current initial test The value is summed up, and after the traversal of each of the initial tests under the current cognitive domain is completed, the value of each of the initial tests under the current cognitive domain is obtained. The total value will The initial test with the largest total value is selected as the target test under the current cognitive domain; after the traversal of each cognitive domain is completed, the target test corresponding to each cognitive domain is obtained, wherein the asymptomatic subject The value represents the Z score reduction of the asymptomatic subject relative to the healthy subject, and the The value represents the Z score reduction of the symptomatic subjects relative to the healthy subjects; The simplified ICAS-related cognitive impairment test generation module is used to sequentially combine the target tests corresponding to each cognitive domain to obtain the simplified ICAS-related cognitive impairment test.

2. The device according to claim 1, characterized in that ,The neuroimaging evaluation results include head MRI evaluation results and head MRA evaluation results; The head MRI assessment results include at least one of whether there is infarction in key brain areas, Fasekas score of white matter lesions, number of cavities in the brain, and grading score of cerebral lobe atrophy; The head MRA evaluation result includes at least one of the presence or absence of intracranial artery stenosis and the proportion of intracranial artery stenosis.

3. The device according to claim 1, characterized in that ,The cognitive impairment assessment module includes: an assessment unit, a test score conversion unit and a cognitive ,function state output unit; The evaluation unit is used to perform a pre-constructed simplified ICAS-related cognitive impairment test on the person to be tested to obtain a test score of each cognitive domain of the person to be tested; The test score conversion unit is used to calculate the Z score corresponding to the test score of each cognitive domain based on the test score of each cognitive domain, wherein the Z score is used to represent the relative level of the test score of each cognitive domain of the person to be tested in the population; The cognitive function status output unit is used to output the cognitive function status of the person to be tested based on the Z score corresponding to the test score of each cognitive domain.

4. The device according to claim 3, characterized in that , the simplified ICAS-related cognitive impairment test includes a life ability domain test, and the test scores of each cognitive domain of the person to be tested include the test score of the life ability domain; The cognitive function status output unit, when outputting the cognitive function status of the person to be tested based on the Z score corresponding to the test score of each cognitive domain, is specifically used to: obtaining a test score of the life ability domain; Based on the Z scores corresponding to the test scores of the cognitive domains and the test scores of the life ability domains, the cognitive function status of the person to be tested is output.

5. The device according to claim 1, characterized in that ,The cognitive function state includes : different cognitive levels, wherein the different cognitive levels correspond to different degrees of cognitive states.

6. The device according to claim 1, characterized in that , also includes: vascular risk factor assessment module; The vascular risk factor assessment module is used to obtain the vascular risk factors of the person to be tested; The result output module is used to determine whether the person to be tested has cognitive impairment related to intracranial atherosclerotic stenosis based on the neuroimaging assessment results, the cognitive function status and the vascular risk factors.

7. The device according to claim 6, characterized in that , the vascular risk factors include at least one of hypertension, diabetes, hyperlipidemia, smoking and drinking.

8. A device for evaluating cognitive impairment in people with intracranial atherosclerotic stenosis, characterized in that: A device for evaluating cognitive impairment in a population with intracranial atherosclerotic stenosis as described in any one of claims 1 to 7.

Images